Healius Crecimiento futuro

Future controles de criterios 3/6

Healius se prevé un crecimiento anual de los beneficios y los ingresos de 90.7% y 4.2% respectivamente. Se prevé que el BPA sea de grow en 101.5% al año. Se prevé que la rentabilidad de los fondos propios sea de 3.5% en 3 años.

Información clave

106.6%

Tasa de crecimiento de los beneficios

94.6%

Tasa de crecimiento del BPA

Crecimiento de los beneficios de Healthcare	24.0%
Tasa de crecimiento de los ingresos	4.6%
Rentabilidad financiera futura	5.3%
Cobertura de analistas	Good
Última actualización	03 Apr 2024

Actualizaciones recientes sobre el crecimiento futuro

Recent updates

Previsiones de crecimiento de beneficios e ingresos

DB:PGZ - Estimaciones futuras de los analistas y datos financieros pasados (AUD Millions)
Fecha	Ingresos	Beneficios	Flujo de caja libre	Flujo de caja operativo	Núm. de analistas medio
6/30/2026	1,892	45	337	371	12
6/30/2025	1,800	26	323	341	13
6/30/2024	1,715	-632	242	274	13
12/31/2023	1,692	-984	217	284	N/A
9/30/2023	1,699	-682	237	309	N/A
6/30/2023	1,707	-380	257	333	N/A
12/31/2022	1,839	35	313	407	N/A
9/30/2022	2,064	164	403	497	N/A
6/30/2022	2,289	292	493	587	N/A
12/31/2021	2,292	226	549	624	N/A
9/30/2021	2,103	146	506	575	N/A
6/30/2021	1,914	66	464	526	N/A
3/31/2021	1,802	75	460	512	N/A
12/31/2020	1,690	83	456	497	N/A
9/30/2020	1,630	83	395	452	N/A
6/30/2020	1,570	83	333	407	N/A
12/31/2019	1,502	110	99	233	N/A
9/30/2019	1,534	83	49	180	N/A
6/30/2019	1,566	57	-2	128	N/A
3/31/2019	1,785	29	23	140	N/A
12/31/2018	1,752	2	48	153	N/A
9/30/2018	1,728	3	74	177	N/A
6/30/2018	1,705	4	99	202	N/A
3/31/2018	1,694	-256	108	215	N/A
12/31/2017	1,683	-516	117	227	N/A
9/30/2017	1,671	-516	N/A	220	N/A
6/30/2017	1,659	-517	N/A	212	N/A
3/31/2017	1,648	-260	N/A	219	N/A
12/31/2016	1,637	-3	N/A	227	N/A
9/30/2016	1,639	18	N/A	256	N/A
6/30/2016	1,642	38	N/A	285	N/A
12/31/2015	1,595	126	N/A	270	N/A
9/30/2015	1,587	121	N/A	255	N/A
6/30/2015	1,580	117	N/A	239	N/A
3/31/2015	1,596	127	N/A	256	N/A
12/31/2014	1,572	118	N/A	271	N/A
9/30/2014	1,548	116	N/A	266	N/A
6/30/2014	1,524	115	N/A	261	N/A
3/31/2014	1,501	134	N/A	256	N/A
12/31/2013	1,478	131	N/A	243	N/A
9/30/2013	1,459	140	N/A	254	N/A
6/30/2013	1,440	150	N/A	264	N/A

Previsiones de crecimiento futuro de los analistas

Ingresos vs. Tasa de ahorro: PGZ se prevé que sea rentable en los próximos 3 años, lo que se considera un crecimiento más rápido que la tasa de ahorro (0.6%).

Beneficios vs. Mercado: PGZ se prevé que sea rentable en los próximos 3 años, lo que se considera un crecimiento del mercado superior a la media.

Beneficios de alto crecimiento: PGZ se espera que sea rentable en los próximos 3 años.

Ingresos vs. Mercado: PGZ(4.2% al año) se prevé que crezca más despacio que el mercado de German (4.8% al año).

Ingresos de alto crecimiento: PGZSe prevé que los ingresos de la empresa (4.2% al año) crezcan más despacio que 20% al año.

Previsiones de crecimiento de los beneficios por acción

Rentabilidad financiera futura

ROE futura: PGZSe prevé que la Rentabilidad de los fondos propios de la empresa sea baja dentro de 3 años (3.5%).

Descubre empresas en crecimiento

Price

Mkt cap

E.Growth

Analysts Target

Price

Mkt cap

E.Growth

Analysts Target

Price

Mkt cap

E.Growth

Analysts Target

Price

Mkt cap

E.Growth

Analysts Target

Healius Crecimiento futuro

Future controles de criterios 3/6

Información clave

Actualizaciones recientes sobre el crecimiento futuro

Healius Limited Decides Not to Provide Earnings Guidance for the Second Half of 2021

Recent updates

High number of new directors

Healius Limited to Report First Half, 2024 Results on Feb 27, 2024

Australian Clinical Labs Limited (ASX:ACL) cancelled the acquisition of Healius Limited (ASX:HLS) from Tanarra Capital Australia Pty Ltd, Perpetual Investment Management Ltd and others.

New minor risk - Shareholder dilution

High number of new directors

Healius Limited Appoints Ravi Jeyaraj as Director

Healius Limited Announces Chair Changes

Healius Limited Announces Chair Changes

Healius Limited has filed a Follow-on Equity Offering in the amount of AUD 187.32 million.

Healius Limited has filed a Follow-on Equity Offering in the amount of AUD 187.32 million.

Healius Limited, Annual General Meeting, Nov 01, 2023

Australian Clinical Labs Limited (ASX:ACL) canceled the acquisition of Healius Limited (ASX:HLS)

Healius Limited Appoints Michael Stanford as Director

Full year 2023 earnings released

Healius Limited to Report Fiscal Year 2023 Results on Aug 30, 2023

Healius Limited Appoints Jan Van Rooyen as Group Executive, Healius Pathology Effective 1 June 2023

High number of new directors

Independent Non Executive Chairman recently bought €65k worth of stock

First half 2023 earnings released: AU$0.045 loss per share (vs AU$0.40 profit in 1H 2022)

Healius Limited Announces Resignation of Alison Stephenson as Company Secretary

Healius Limited to Report First Half, 2023 Results on Feb 27, 2023

Nexus Hospitals entered into an agreement to acquire Montserrat Healthcare Pty Ltd from Healius Limited (ASX:HLS).

QIC Reportedly Set to Clinch Healius Day Hospital Unit for $140 Million Plus

MD, CEO & Director recently sold €424k worth of stock

Brookfield Reportedly Drops Out of Race to Buy Healius

Independent Non Executive Director recently bought €57k worth of stock

Full year 2022 earnings released: EPS: AU$0.50 (vs AU$0.11 in FY 2021)

Healius Limited Announces Fully Franked Ordinary Paid Dividend for the Six Months Ended June 30, 2022, Payable on September 21, 2022

Healius Limited, Annual General Meeting, Oct 20, 2022

Healius Reportedly Launches Day Surgery Sale Process

Healius Reportedly Keeps Watching Brief on Integral Diagnostics

Healius Limited to Report Fiscal Year 2022 Results on Aug 31, 2022

Healius Reportedly Seeks X-Ray Factor in Day Surgeries Sale Plan

Healius Limited Announces Appointment of John Mattick as Non-Executive Director

Upcoming dividend of AU$0.10 per share

First half 2022 earnings: EPS in line with expectations, revenues disappoint

Healius Limited Announces Ordinary Fully Paid Dividend for the Period of Six Months December 31, 2021, Payable April 15, 2022

Healius Limited to Report First Half, 2022 Results on Feb 23, 2022

Healius Limited (ASX:HLS) acquired Agilex Biolabs Pty Ltd.

Healius Limited (ASX:HLS) entered into an agreement to acquire Agilex Biolabs Pty Ltd for approximately AUD 300 million.

MD, CEO & Director recently sold €457k worth of stock

Upcoming dividend of AU$0.068 per share

Full year 2021 earnings released: EPS AU$0.11 (vs AU$0.12 in FY 2020)

Healius Limited (ASX:HLS) acquired Axis Diagnostic Holdings Pty Limited.

Healius Reportedly to Sale Day Surgeries

Healius Limited Decides Not to Provide Earnings Guidance for the Second Half of 2021

Healius Limited Appoints Kate McKenzie as A Non-Executive Director Effective from 25 February 2021

Healius Limited(ASX:HLS) dropped from S&P/ASX 100 Index

New 90-day high: €2.46

New 90-day high: €2.42

New 90-day high: €2.24

BGH Capital completed the acqusition of Primary Care Business of Healius Ltd from Healius Limited (ASX:HLS) for AUD485 million.

Healius Limited Announces Retirement of Arlene Tansey as Non-Executive Director

New 90-day high: €2.12

Healius Limited to Report Fiscal Year 2021 Results on Aug 20, 2021

Full year earnings released - EPS €0.12

New 90-day high - €2.02

Full year earnings released - EPS €0.12

New 90-day high - €1.93

Previsiones de crecimiento de beneficios e ingresos

Previsiones de crecimiento futuro de los analistas

Previsiones de crecimiento de los beneficios por acción

Rentabilidad financiera futura

Descubre empresas en crecimiento